Endometriosis-associated lesions during or after long-term estrogen-only therapy following hysterectomy: 2 cases.
4 affiliations
- 1Department of Obstetrics and Gynecology, Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
- 2Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
- 3Department of Pathology, Chiba University Hospital, Chiba 260-8677, Japan.
- 4Department of Diagnostic Pathology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Abstract
Estrogen-only menopausal hormone therapy (MHT) is prescribed after hysterectomy; however, occult or residual endometriotic tissue may remain hormonally responsive. We report 2 women in whom endometriotic lesions were identified during or after long-term transdermal estrogen-only MHT after hysterectomy and bilateral salpingo-oophorectomy. The first patient was a 48-year-old woman treated for International Federation of Gynecology and Obstetrics 2009 stage IA, grade 1 endometrioid endometrial carcinoma at 44 years of age. Her estrogen-progestogen MHT for treatment-related premature ovarian insufficiency was changed to transdermal estrogen-only MHT. About 3 years later, she developed a progressively enlarging ileocecal mass, with resection revealing endometriosis. The second patient was a 54-year-old woman who had undergone hysterectomy and bilateral salpingo-oophorectomy for endometriosis at 46 years of age. She received transdermal estrogen-only MHT for approximately 6 years and was diagnosed with atypical endometrial hyperplasia in vaginal cuff endometriosis 1 year after estrogen withdrawal. These observations do not establish a causal relationship between estrogen-only MHT and lesion development. Occult disease, residual disease, or iatrogenic implantation remain plausible explanations. Nevertheless, these cases highlight that new abdominal masses or posthysterectomy vaginal bleeding during or after MHT warrant careful evaluation with histopathologic confirmation. MHT should be individualized according to current clinical guidelines.
Related
- High-resolution spatial transcriptomics reveals fibroblast and neuroimmune microenvironments in endometriosis lesions
- Delayed Umbilical Extrusion of a Ventriculoperitoneal Shunt Following Robotic-Assisted Laparoscopic Hysterectomy: A Case Report
- Real-World Guideline Concordance and Potential Overtreatment Following Primary Radical Hysterectomy for Early-Stage Cervical Cancer
- Association of a multimodal perioperative nutritional/ERAS care pathway with postoperative infectious complications following radical hysterectomy for cervical cancer: a retrospective nonconcurrent cohort study
- Estrogen Receptor-Mediated Effects of a Phytoestrogen-Rich Soy-Based Diet on Metabolic Health Following Ovariectomy in Aged Mice
BibTeX
@article{sugimoto2026endometriosisassociated,
title = {{Endometriosis-associated lesions during or after long-term estrogen-only therapy following hysterectomy: 2 cases.}},
author = {Daisuke Sugimoto and Hiroshi Ishikawa and Miyuki Harada and Natsuho Kaneda and Keisuke Matsusaka and Kaori Koga},
journal = {JCEM case reports},
year = {2026},
month = oct,
doi = {10.1210/jcemcr/luag329},
url = {https://europepmc.org/article/MED/42923654},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Endometriosis-associated lesions during or after long-term estrogen-only therapy following hysterectomy: 2 cases.
AU - Daisuke Sugimoto
AU - Hiroshi Ishikawa
AU - Miyuki Harada
AU - Natsuho Kaneda
AU - Keisuke Matsusaka
AU - Kaori Koga
PY - 2026
DA - 2026/10/22
JO - JCEM case reports
DO - 10.1210/jcemcr/luag329
UR - https://europepmc.org/article/MED/42923654
AB - Estrogen-only menopausal hormone therapy (MHT) is prescribed after hysterectomy; however, occult or residual endometriotic tissue may remain hormonally responsive. We report 2 women in whom endometriotic lesions were identified during or after long-term transdermal estrogen-only MHT after hysterectomy and bilateral salpingo-oophorectomy. The first patient was a 48-year-old woman treated for International Federation of Gynecology and Obstetrics 2009 stage IA, grade 1 endometrioid endometrial carcinoma at 44 years of age. Her estrogen-progestogen MHT for treatment-related premature ovarian insufficiency was changed to transdermal estrogen-only MHT. About 3 years later, she developed a progressively enlarging ileocecal mass, with resection revealing endometriosis. The second patient was a 54-year-old woman who had undergone hysterectomy and bilateral salpingo-oophorectomy for endometriosis at 46 years of age. She received transdermal estrogen-only MHT for approximately 6 years and was diagnosed with atypical endometrial hyperplasia in vaginal cuff endometriosis 1 year after estrogen withdrawal. These observations do not establish a causal relationship between estrogen-only MHT and lesion development. Occult disease, residual disease, or iatrogenic implantation remain plausible explanations. Nevertheless, these cases highlight that new abdominal masses or posthysterectomy vaginal bleeding during or after MHT warrant careful evaluation with histopathologic confirmation. MHT should be individualized according to current clinical guidelines.
SN - 2755-1520
ER -